Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP. The company also develops Baxdela that in a Phase III clinical trial for treating community-acquired bacterial pneumonia (CABP)); Fusidic Acid, which is in Phase III clinical trial for treating ABSSSIs; and radezolid, a melinta molecule that is in Phase II clinical trial for dermatological applications, as well as ESKAPE pathogen program, which is in preclinical stage targeting superbugs. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals, Inc. and changed its name to Melinta Therapeutics, Inc. in October 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:MLNT
CUSIP15130J10
Phone312-767-0291
Debt
Debt-to-Equity Ratio0.53
Current Ratio1.48
Quick Ratio1.20
Price-To-Earnings
Trailing P/E Ratio-0.28
Forward P/E Ratio-1.47
P/E GrowthN/A
Sales & Book Value
Annual Sales$33.86 million
Price / Sales5.61
Cash FlowN/A
Price / CashN/A
Book Value$2.31 per share
Price / Book2.62
Profitability
EPS (Most Recent Fiscal Year)($21.86)
Net Income$-58,910,000.00
Net Margins-327.21%
Return on Equity-49.88%
Return on Assets-28.93%
Miscellaneous
Employees300
Outstanding Shares31,370,000
Market Cap$202.33
Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions
What is Melinta Therapeutics' stock symbol?
Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."
How were Melinta Therapeutics' earnings last quarter?
Melinta Therapeutics, Inc. (NASDAQ:MLNT) issued its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.27) by $0.32. The biotechnology company earned $14.84 million during the quarter, compared to analysts' expectations of $13.13 million. Melinta Therapeutics had a negative return on equity of 49.88% and a negative net margin of 327.21%. View Melinta Therapeutics' Earnings History.
When is Melinta Therapeutics' next earnings date?
What price target have analysts set for MLNT?
8 Wall Street analysts have issued 12-month target prices for Melinta Therapeutics' stock. Their forecasts range from $2.00 to $15.00. On average, they expect Melinta Therapeutics' stock price to reach $6.00 in the next year. This suggests that the stock has a possible downside of 0.8%. View Analyst Ratings for Melinta Therapeutics.
What is the consensus analysts' recommendation for Melinta Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Melinta Therapeutics stock?
Here are some recent quotes from research analysts about Melinta Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, ". We are initiating coverage of Melinta’s stock with an Overweight rating and $15 PT. Upward earnings revisions and multiple expansion will drive the shares higher, in our view. We think a greater appreciation for the company’s four commercial, antibiotic drugs (Baxdela, and its growing pipeline (new drugs, international expansion, additional indications) will increase earnings estimates to levels not yet reflected in consensus expectations. Also, MLNT is considering adjacent opportunities, which means it could become a diversified hospital company. This should improve its trading multiple, in our view." (7/1/2018)
- 2. According to Zacks Investment Research, "Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT. " (3/17/2018)
Are investors shorting Melinta Therapeutics?
Melinta Therapeutics saw a decrease in short interest in the month of May. As of May 31st, there was short interest totalling 1,329,597 shares, a decrease of 28.4% from the May 15th total of 1,857,164 shares. Based on an average daily volume of 894,565 shares, the short-interest ratio is presently 1.5 days. Approximately 3.9% of the shares of the stock are sold short. View Melinta Therapeutics' Current Options Chain.
Who are some of Melinta Therapeutics' key competitors?
Some companies that are related to Melinta Therapeutics include Inflarx (IFRX), AC Immune (ACIU), Kiniksa Pharmaceuticals (KNSA), CymaBay Therapeutics (CBAY), Rocket Pharmaceuticals (RCKT), Amphastar Pharmaceuticals (AMPH), NuCana (NCNA), AMAG Pharmaceuticals (AMAG), Eidos Therapeutics (EIDX), Adamas Pharmaceuticals (ADMS), GlycoMimetics (GLYC), Cara Therapeutics (CARA), Abeona Therapeutics (ABEO), Aptinyx (APTX) and ChemoCentryx (CCXI).
Who are Melinta Therapeutics' key executives?
Melinta Therapeutics' management team includes the folowing people:
- Dr. Erin M. Duffy Ph.d., Chief Scientific Officer (Age 50)
- Mr. Daniel Mark Wechsler, Pres & CEO (Age 50)
- Dr. Thomas A. Steitz Ph.D., Co-Founder
- Dr. Peter B. Moore Ph.D., Co-Founder
- Dr. William L. Jorgensen Ph.D., Co-Founder
Has Melinta Therapeutics been receiving favorable news coverage?
News stories about MLNT stock have trended somewhat positive recently, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Melinta Therapeutics earned a coverage optimism score of 0.15 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.05 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Melinta Therapeutics' major shareholders?
Melinta Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Pennsylvania Trust Co (0.85%). Company insiders that own Melinta Therapeutics stock include David N Gill, Dov A Md Goldstein, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics.
Which institutional investors are selling Melinta Therapeutics stock?
How do I buy shares of Melinta Therapeutics?
Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Melinta Therapeutics' stock price today?
One share of MLNT stock can currently be purchased for approximately $6.05.
How big of a company is Melinta Therapeutics?
Melinta Therapeutics has a market capitalization of $202.33 million and generates $33.86 million in revenue each year. The biotechnology company earns $-58,910,000.00 in net income (profit) each year or ($21.86) on an earnings per share basis. Melinta Therapeutics employs 300 workers across the globe.
How can I contact Melinta Therapeutics?
Melinta Therapeutics' mailing address is 300 GEORGE STREET SUITE 301, NEW HAVEN CT, 06511. The biotechnology company can be reached via phone at 312-767-0291 or via email at [email protected]
MarketBeat Community Rating for Melinta Therapeutics (NASDAQ MLNT)
MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe MLNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
